A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants
- Conditions
- Subjects With Unresectable Cholangiocarcinoma With FGFR2 Gene Fusion
- Registration Number
- JPRN-jRCT2031200214
- Lead Sponsor
- Clinical, Medicine Creation Japan and Asia Clinical Development Department
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 42
Participants who meet all of the following criteria will be eligible for participation in the study
1. Body mass index (BMI) between 18.5 to 25.0 kilogram per square meter (kg/m^2), inclusive, at screening
Participants who meet any of the following criteria will be excluded from this study:
1. Following ocular disorders
a. Current evidence of Grade 2 or higher corneal disorder
b. Current evidence of active macular disorder (example, age-related macular degeneration, central serous chorioretinal disease)
2. Any clinically abnormal symptom or organ impairment found by medical history at screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at screening
3. A prolonged QT/QTc interval (QT interval with Fridericia's correction [QTcF] greater than [>] 480 millisecond [ms]) demonstrated on ECG at screening or baseline
4. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at screening
5. Known history of allergies or reactions to rabeprazole or rifampin or known anaphylactic reaction to any drugs at screening
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of compound(s)
- Secondary Outcome Measures
Name Time Method